Studying the Clinical Trial Experiences of Patients With Mesothelioma

NCT05819580 | Not Yet Recruiting

• 1 other identifier: 80693772
• Study Type: observational
• Target: 500
• Locations: 0 countries
• Sites: N/A

Brief Summary

Medical research participation percentages haven't always been fully representative of a given demographic. The goal is to find out which aspects of a clinical study may make it more difficult for patients to take part or see it through. The data will be evaluated through different demographic lenses and identify trends that could help improve the experience of future mesothelioma patients during clinical trials.

Conditions

Mesothelioma

Keywords

mesothelioma

Outcome Measures

Primary Outcomes (2)

• Rate of patients who decide to enroll in a mesothelioma medical study.

  3 months

• Number of mesothelioma patients who remain in clinical trial until completion.

  12 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Mesothelioma patients who are actively considering involvement in an observational clinical trial, but have not yet completed enrollment and registration.

You may qualify if:

• Must have a medical diagnosis of mesothelioma that has been confirmed by a physician.
• Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed.
• Willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study.

You may not qualify if:

• Pregnant or lactating woman
• Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent.
• Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug(s) administration or interfere with the interpretation of safety results

Sponsors & Collaborators

• Power Life Sciences Inc.: lead

Related Publications (3)

• Sinn K, Mosleh B, Hoda MA. Malignant pleural mesothelioma: recent developments. Curr Opin Oncol. 2021 Jan;33(1):80-86. doi: 10.1097/CCO.0000000000000697.

  PMID: 33186182 BACKGROUND

• Jakobsen JN, Sorensen JB. Review on clinical trials of targeted treatments in malignant mesothelioma. Cancer Chemother Pharmacol. 2011 Jul;68(1):1-15. doi: 10.1007/s00280-011-1655-3. Epub 2011 May 7.

  PMID: 21553148 BACKGROUND

• Lau B, Boyer M, Lee JH, Kao S. Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes. Clin Lung Cancer. 2020 Jul;21(4):378-383.e1. doi: 10.1016/j.cllc.2020.01.007. Epub 2020 Mar 7.

  PMID: 32249197 BACKGROUND

MeSH Terms

Conditions

Mesothelioma

Condition Hierarchy (Ancestors)

Adenoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Mesothelial

Study Officials

• Michael B Gill

  Power Life Sciences Inc.

  STUDY DIRECTOR

Central Study Contacts

Michael B Gill

CONTACT

415-900-4227; bask@withpower.com

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 6, 2023
• First Posted: April 19, 2023
• Study Start: May 1, 2024
• Primary Completion: May 1, 2025
• Study Completion: May 1, 2026
• Last Updated: April 25, 2023

Record last verified: 2023-04